Clinical data | |
---|---|
Pronunciation | peg val' i ase |
Trade names | Palynziq |
Other names | Pegvaliase-pqpz; PEG-PAL; RAvPAL-PEG |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618057 |
License data |
|
Pregnancy category | |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C10872H17216N3040O3300S80[7][8] |
Molar mass | 245880.10 g·mol−1 |
Pegvaliase, sold under the brand name Palynziq, is a medication used for the treatment of the genetic disease phenylketonuria.[5][9][10] It is a phenylalanine (Phe)‑metabolizing enzyme.[5] Chemically, it is a pegylated derivative of the enzyme phenylalanine ammonia-lyase that metabolizes phenylalanine to reduce its blood levels.[5]
The most common adverse events include injection site reactions, joint pain, hypersensitivity reactions, headache, generalized skin reactions lasting at least 14 days, pruritus (itchy skin), nausea, dizziness, abdominal pain, throat pain, fatigue, vomiting, cough and, diarrhea.[9]
It was approved by the US Food and Drug Administration (FDA) for use in the United States in 2018.[9] The FDA considers it to be a first-in-class medication.[11]